Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 99%
filed 2026-06-22
Item 7.01
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the target at approximately $10.9 billion. The press release explicitly states "AbbVie will acquire all outstanding shares of Apogee" and describes this as a material acquisition that "complements AbbVie's existing immunology portfolio." This is a clear material acquisition event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 98%
filed 2026-06-22
EX-99.1
Fairfax completed an offering of C$300 million aggregate principal amount of 4.40% Senior Notes due 2036, bringing total outstanding notes of this series to C$700 million. This is a material creation of a direct financial obligation through debt issuance, disclosed in a news release announcing the completion of the offering. The company intends to use proceeds for general corporate purposes including refinancing, repayment, or acquisition opportunities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-22
Item 8.01
The filing discloses three stockholder complaints (two in New York, one in Pennsylvania) and eleven demand letters challenging the adequacy of disclosures in the Definitive Proxy Statement regarding a proposed merger. The complaints seek to enjoin the merger and claim damages, representing material litigation that could affect the transaction's consummation and impose legal costs and business delays on the registrant.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-22
Item 8.01
Definium announced positive topline results from its Phase 3 Emerge study of DT120 ODT for major depressive disorder, meeting the primary endpoint with an 8.1-point placebo-adjusted MADRS improvement (p<0.0001) and demonstrating rapid, durable efficacy with a favorable safety profile. This represents a material clinical development milestone advancing the company's late-stage program toward potential FDA submission.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-22
Item 7.01
Booz Allen announced entry into a definitive agreement to acquire Ultra I&C Mission Solutions business for $720 million, a material acquisition of a defense technology business. The press release explicitly states the company "has entered into a definitive agreement" and describes the strategic rationale, expected financial performance (double-digit revenue growth, EBITDA margins above 20%), and expected closing timeline (Q2 FY2027). This is a classic Item 1.01 material acquisition disclosure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-22
EX-99.1
GFL announces a proposed private offering of US$750 million in senior notes due 2031, creating a new direct financial obligation. The company explicitly states the Notes will be issued by a U.S. subsidiary and guaranteed by GFL and certain other subsidiaries. This is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and leverage, particularly given the stated intent to maintain leverage in the mid-3.0x range and fund the SECURE Waste Infrastructure Corp. acquisition.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-22
Manchester United announced the acquisition of a 25-acre site to build a new 100,000-seat stadium, described as a "major milestone" and "generational opportunity." This is a material strategic and operational development involving significant capital commitment and long-term business transformation. While not fitting the specific categories of M&A (which typically involve acquisition of another company), it represents a major operational and capital project that would affect a reasonable investor's assessment of the club's strategic direction and financial obligations.
View raw filing on EDGAR →
8-K
Restatement
confidence 98%
filed 2026-06-22
Item 4.02
The Audit Committee determined on June 17, 2026 that previously issued unaudited condensed consolidated financial statements for the three and nine months ended January 31, 2026 require restatement and should no longer be relied upon. The error involved a material goodwill impairment charge of $89.4 million related to the Space reporting unit, resulting in understated net loss by $87.3 million and overstated total assets by $89.4 million. The company also identified a material weakness in internal controls over financial reporting related to the goodwill impairment analysis.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Two directors, David Wodlinger and Henry Albers, resigned from the Board effective June 17, 2026. While the filing notes their resignations were not due to disagreement with management, the departure of two board members designated by a significant shareholder (Arlington Capital Partners) represents a material change in board composition and governance structure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-06-22
The filing announces an amendment to an existing long-term loan agreement with China Development Bank, revising the second tranche from RMB 1.23 billion to RMB 700 million and reducing the annual fixed interest rate from 4.98% to 4.30%. While this is technically an amendment to existing debt rather than a new issuance, it materially modifies the terms of a direct financial obligation and would be of interest to investors assessing the company's capital structure and financing costs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Stone Point Credit Income Fund disclosed the unregistered sale of 1,013,220.501 common shares at NAV for $25,000,000 aggregate offering price, plus an additional 495,413.844 shares for $12,223,742, pursuant to subscription agreements with accredited investors under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities exempt from registration, material to investors assessing the Fund's capital structure and the dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-22
The 6-K announces Capital Markets Board (CMB) approval on June 17, 2026 for Turkcell's issuance of domestic debt securities with a 15 billion TRY issue limit under private placement to qualified investors. This represents creation of a new direct financial obligation and is a material capital-raising event for the registrant.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-06-22
The filing discloses the resignation of Ms. Enriqueta Felip Font from her position as a member of the Board of Directors and the Sustainability, Communication and Reputation Committee, effective June 19, 2026. While the filing also announces the appointment of a replacement director (Ms. Ester Masllorens Llinàs) and committee member (Mr. Pascal Ravery), the principal disclosed action is the departure of an existing board member. Board-level departures are material to investors' assessment of governance and continuity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Third Point Private Capital Partners completed an unregistered sale of 384,766 Class I common shares for $10,000,000 as of May 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions to accredited investors and non-U.S. persons.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This Item 5.07 disclosure reports the results of ArriVent BioPharma's June 18, 2026 annual meeting of stockholders, including the election of three Class II directors (James Healy, John Hohneker, and Stuart Lutzker) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing provides detailed vote tallies for each matter, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-22
Item 4.01
BPM LLP resigned as the Company's independent registered public accounting firm effective immediately on June 15, 2026. This is a clear auditor change under Item 4.01. The disclosure confirms no adverse opinions, disagreements, or reportable events, which mitigates concerns but does not change the materiality of the auditor departure itself—a change in certifying accountant is material to investors assessing financial reporting reliability.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
Item 5.07 discloses the final voting results from Cypherpunk Technologies' 2026 Annual Meeting of Stockholders held on June 18, 2026. The section presents tabulated results for three matters: election of Class III directors (Will McEvoy and Nissim Mashiach), advisory approval of executive compensation, and ratification of EisnerAmper LLP as independent auditor. This is a textbook shareholder_vote_results disclosure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-22
EX-99.1
This exhibit is an Eighth Supplemental Indenture dated June 19, 2026, providing for the issuance of $500 million in 5.55% Medium Term Notes (unsecured), Series 8, due June 19, 2031, by Brookfield Property Finance ULC. The document establishes the terms, conditions, and covenants governing this new debt issuance, including interest payment dates, redemption provisions, and change-of-control protections. This is a material creation of direct financial obligation under Item 2.03 of the 8-K taxonomy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-22
Item 1.01
The filing discloses amendment of an existing $15 million loan agreement with Byline Bank, extending the maturity date from June 18, 2026 to June 18, 2028 and increasing tangible net worth requirements from $70 million to $80 million. While this is technically an amendment to existing debt rather than a new issuance, it materially modifies the registrant's direct financial obligations and extends the credit facility's term, which affects the company's capital structure and financial flexibility. The amendment also introduces a new default trigger tied to Excess Net Capital maintenance, which is material to investors assessing the company's financial stability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-22
Item 5.02
Christopher Currier was appointed as Chief Accounting Officer (Principal Accounting Officer) effective June 16, 2026, promoted from Senior Vice President and Controller, succeeding Michael H. Schwerdtman's retirement from the role.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-22
Item 8.01
People Inc entered into a Voting Agreement on June 22, 2026 with Barry Diller, Diane von Furstenberg, and Alexander von Furstenberg, whereby these parties controlling approximately 46.4% of voting power agreed to vote their shares in excess of 48.5% in the same proportion as other shareholders, subject to independent committee approval for written consent actions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 3.02
The Company issued 200,000 shares of Class B common stock to CEO/Chairman Huan Liu at $2.00 per share ($400,000 gross proceeds) in an unregistered private placement under Regulation S and Section 4(a)(2). The restricted securities issuance dilutes existing shareholders and represents a material insider transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
CrowdStrike held its Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on four proposals: election of Class I directors (Johanna Flower and Denis J. O'Leary), ratification of PricewaterhouseCoopers LLP as independent auditor, approval of an amendment to limit officer liability under Delaware law, and an advisory vote on supermajority voting provisions. All proposals received shareholder approval with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-22
Item 5.02
Craig Sasser was appointed Chief Operating Officer effective July 1, 2026, a material C-suite promotion from Regional Vice President, with a base salary of $600,000 and 90% target bonus. Additionally, Briston Blair was promoted to Chief Strategy & Innovation Officer. These senior leadership appointments reflect significant governance and operational changes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder voting results from AdaptHealth's June 18, 2026 annual meeting of stockholders. The filing reports the outcomes of three proposals: election of nine directors, ratification of KPMG LLP as independent auditor, and a non-binding advisory vote on named executive officer compensation. All three proposals passed with substantial majorities. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment for the fiscal year.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
Deep Fission completed a public offering of 2.5 million shares at $16.00 per share, generating $40 million in gross proceeds, with an additional 375,000-share greenshoe option granted to underwriters. While this is a registered public offering (not an unregistered private placement), it represents a material dilutive issuance of equity that would significantly affect a reasonable investor's assessment of ownership and capital structure, particularly for a newly public company (trading began June 18, 2026).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-22
Item 2.02
TechPrecision Corporation issued a press release on June 22, 2026, announcing financial results for the three months and fiscal year ended March 31, 2026. The disclosure includes consolidated revenue ($31.6M for FY2026), gross profit ($5.0M), net loss ($1.6M), and forward guidance for FY2027 (revenue $35.0M-$37.0M, EBITDA $3.0M-$4.0M). This is a standard earnings release disclosing quarterly and annual financial results, furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This Item 5.07 disclosure reports the results of Terra Property Trust's June 18, 2026 annual stockholder meeting, including the election of all five director nominees and ratification of KPMG LLP as independent auditor. The filing presents detailed voting tallies for each proposal, which is the core content of shareholder vote results disclosures and material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
The Company issued 2,727,272 warrants to Maxim Group LLC as part of a settlement arrangement, with the warrants exercisable into common stock at $0.6325 per share. This represents a dilutive equity issuance to a placement agent in connection with the Company's at-the-market offering program. The warrant issuance, combined with the $1,050,000 cash fee and future 3% commission on ATM proceeds, constitutes material consideration for capital-raising services and would materially dilute existing shareholders.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-06-22
Item 1.01
The filing discloses entry into a new investment advisory agreement with identical economic terms to the prior agreement, but the material event is the change in control of the Advisor (Stellus Capital Management) to Ridgepost Capital, LLC, which triggered the need for stockholder approval and renewal of the advisory agreement. While this involves a material definitive agreement, the core governance issue is the change in the investment advisor's ownership and control, which is a governance matter distinct from the specific advisory agreement mechanics.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-22
Item 1.01
The filing discloses entry into a new investment advisory agreement on June 22, 2026, which became effective upon the closing of an acquisition of Stellus Capital Management, LLC by Ridgepost Capital, LLC—a change of control event. While the agreement terms are identical to the prior agreement, the triggering event is a material acquisition that resulted in a change in control of the Advisor, making this a material M&A activity disclosure under Item 1.01.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-22
EX-99.1
This exhibit discloses ZTO Express's acquisition of the remaining 36.20% shareholding in TuXi Tech (567.5 million shares) for approximately RMB1,305.3 million through Share Purchase Agreements dated June 22, 2026. Upon completion, TuXi Tech will become a wholly-owned subsidiary. This is a material acquisition that will consolidate the company's ownership of a last-mile delivery platform and is explicitly identified as a connected transaction under Hong Kong Listing Rules Chapter 14A.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-06-22
Item 8.01
The board approved a new $50.0 million share repurchase program on June 19, 2026, which is a return of capital to shareholders. Share repurchases are classified as dividend_distribution events under the taxonomy, as they represent distributions to holders. The program is material to investors as it signals capital allocation strategy and affects share count and earnings per share.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-22
Item 8.01
CNH Industrial Capital LLC priced and issued $600 million in aggregate principal amount of 4.950% senior unsecured notes due 2031. This is a creation of a new direct financial obligation through debt issuance, with the net proceeds intended for working capital, general corporate purposes, and potential repayment of existing indebtedness. The transaction is material to investors as it represents a significant capital-raising event and increases the company's debt obligations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-22
Item 1.01
Apogee entered into two material agreements with Paragon on June 17, 2026: an antibody discovery agreement and an exclusive worldwide license agreement for IL-31R antibodies. The license agreement grants Apogee exclusive rights to develop and commercialize IL-31R-directed antibodies with up to $23.25 million in milestone payments and low-single-digit royalties on net sales. While this is a material contract that would affect a reasonable investor's assessment of the company's pipeline and strategic partnerships, it does not fit the specific M&A, financing, or governance categories—it is a research and development partnership and licensing arrangement that is operational in nature.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-22
Item 1.01
Apogee entered into a definitive Agreement and Plan of Merger with AbbVie on June 18, 2026, under which AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, valuing the company at approximately $10.9 billion. The transaction constitutes a change of control with Apogee surviving as a wholly owned subsidiary, subject to customary closing conditions including shareholder approval and regulatory clearances, with expected closing in Q3 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-06-22
Item 5.07
Holders of Apogee's non-voting common stock executed written consent adopting entry into the Merger Agreement with AbbVie, with consummation remaining subject to affirmative vote of a majority of voting common stock on the $10.9 billion acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
Daniel M. Krawczyk was appointed as Chief Executive Officer and President of Rayonier Advanced Materials, effective June 22, 2026, and concurrently appointed to the Board as a Class III director. The appointment includes compensatory arrangements comprising a base salary of $1,000,000, target bonus of 100%, equity grants totaling $3,300,000, a sign-on bonus of $750,000, and an inducement LPU award of $1,750,000.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-22
EX-99.1
Castor Maritime announces entry into an agreement to acquire a 2023-built Kamsarmax bulk carrier vessel for $37.5 million through a wholly-owned subsidiary. The acquisition is a material capital deployment that will expand the company's fleet from 9 to 10 vessels and represents a significant asset purchase in the shipping business. The disclosure explicitly states the acquisition is expected to close by end of quarter, subject to customary closing conditions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
The filing announces the appointment of Asad Rahman as Vice President and Chief Financial Officer effective June 30, 2026, with over 25 years of finance and accounting experience from Mars and S.C. Johnson. While the section also discloses David W. Johnson's departure from the CFO role, the principal disclosed action centers on the appointment of the new CFO and his compensatory arrangement ($200,000 restricted stock award). This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Balchem's Annual Meeting of Shareholders held June 18, 2026. The filing reports voting outcomes on three matters: election of two Class 3 directors (David Fischer and Daniel Knutson), ratification of RSM US LLP as independent auditor, and advisory approval of named executive officer compensation. All three votes passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 8.01
The Company completed an initial public offering of 5.5 million shares at $12.50 per share, generating approximately $68.75 million in gross proceeds. This material capital-raising event significantly affects the registrant's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-22
Item 7.01
The fund declared regular distributions per share for each class of common shares at $0.20 gross per share, with specified record and payment dates.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
comScore held its Annual Meeting of Stockholders on June 16, 2026, at which stockholders voted on four proposals: election of two Class I directors (Kline and Wendling), advisory approval of named executive officer compensation, ratification of Deloitte & Touche LLP as independent auditor, and approval of an amendment to the 2018 Equity and Incentive Compensation Plan increasing available shares by 3,000,000. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-22
Item 5.07
This disclosure reports the results of the 2026 Annual Meeting of Members held on June 16, 2026, where three board managers were elected from three geographical districts with specific voting tallies provided for each candidate. The filing directly corresponds to Item 5.07 (Submission of Matters to Vote of Security Holders) and presents the outcome of shareholder/member votes on director elections, which is material to investors' understanding of corporate governance and board composition.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-22
EX-99.1
BrainsWay announced expansion of insurance coverage for its SWIFT Accelerated Deep TMS protocol, with eight major payers and the VA now covering the treatment, representing over 57 million covered lives. This is a material operational/commercial milestone reflecting improved market access and reimbursement for the company's core product, but does not fit the specific event categories (not earnings, M&A, litigation, or other named types). The expansion of favorable coverage policies is a significant business development that would affect investor assessment of the company's commercial prospects.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-06-22
EX-99.1
Aura Minerals' Board has approved a US$200 million share repurchase program for common shares and Brazilian Depositary Receipts, effective June 18, 2026 through June 18, 2027. The press release explicitly frames this as a capital return mechanism alongside dividends: "we maintain a clear focus on capital discipline and value creation through a balanced approach that combines robust dividend payments, opportunistic share buybacks." Share repurchases are a form of capital distribution to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs." The program is material as it represents a significant commitment of capital (US$200 million) and signals management confidence in cash generation and shareholder returns.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-22
EX-99.1
This press release discloses exploration drilling results at Alamos Gold's Island Gold District, reporting new high-grade mineralization zones and extensions across multiple targets (Island West Extension, Island West up-plunge, NS1/NS4 zones, Cline-Pick, Edwards mines). The company budgeted $43 million for 2026 exploration and reports 50,000 m of planned underground drilling. While the results describe potential sources of additional mill feed and production growth, this is an operational/exploration milestone rather than a discrete event fitting other categories. The disclosure is material as it describes significant exploration upside that could affect investor assessment of the company's growth prospects and reserve base.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-22
EX-99.1
OPC Energy Ltd., a Kenon subsidiary, has received tariff approval from the Israeli Electricity Authority for the Hadera power plant expansion project (850 MW combined-cycle natural gas facility) and confirmation that the project satisfies conditions for financial closing. This is a material operational and regulatory milestone for a major capital project, but does not fit the discrete event categories (M&A, debt issuance, impairment, etc.); it is a strategic business development—regulatory approval enabling project advancement—best classified as operational_other.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-22
The 6-K discloses results of an annual general meeting of shareholders held on June 18, 2026, at which three proposals were voted on and all were approved by the requisite shareholder vote. This is a direct disclosure of shareholder vote results, matching the definition of shareholder_vote_results (Item 5.07 equivalent). The materiality is high because shareholder votes on proposals at annual meetings are material governance events affecting the registrant's direction and capital structure.
View raw filing on EDGAR →